Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
REVENUE
Total revenue	$ 279	$ 410
COSTS AND EXPENSES
General and administrative	8,932	16,978
Research and development	6,312	8,742
Depreciation and amortization	78	72
Provision for loss on receivable from Cornerstone Pharmaceuticals pursuant to line of credit		25,000
Provision for losses on related party receivables		10,095
Loss from operations	(15,043)	(60,477)
Interest expense		(6)
Interest income	3,253	201
Impairment of investments - Other Pharmaceuticals	(334)
Impairment of cost method investment - Cornerstone Pharmaceuticals		(79,141)
Realized gain (loss) on available-for-sale securities	154	(45)
Realized gain on investment in equity securities	309
Unrealized gain on investment in equity securities	33
Unrealized gain (loss) on investments	33
Loss from continuing operations before income taxes	(8,745)	(139,972)
Benefit from income taxes	255
Consolidated net loss from continuing operations	(8,693)	(140,547)
Discontinued Operations (Note 3)
Loss from discontinued operations related to 520 Property	(306)	(1,830)
Gain on disposal of 520 Property	6,784
Income (loss) from discontinued operations	6,478	(1,830)
Consolidated net loss	(2,215)	(142,377)
Net loss attributable to noncontrolling interests	(339)	(17,719)
Net loss attributable to Rafael Holdings, Inc.	(1,876)	(124,658)
OTHER COMPREHENSIVE LOSS
Consolidated net loss	(2,215)	(142,377)
Unrealized loss on available-for-sale securities	(290)	(63)
Foreign currency translation adjustment	(42)	(5)
Total comprehensive loss	(2,547)	(142,445)
Comprehensive loss attributable to noncontrolling interests	(336)	(17,746)
Total comprehensive loss attributable to Rafael Holdings, Inc.	$ (2,211)	$ (124,699)
Basic and diluted:
Continuing operations (in Dollars per share)	$ (0.36)	$ (6.22)
Discontinued operations (in Dollars per share)	0.28	(0.09)
Total basic and diluted loss per share (in Dollars per share)	$ (0.08)	$ (6.31)
Weighted average number of shares used in calculation of loss per share
Basic and diluted (in Shares)	23,263,211	19,767,342
Rental – Third Party
REVENUE
Total revenue	$ 171	$ 179
Rental – Related Party
REVENUE
Total revenue	108	111
Other – Related Party
REVENUE
Total revenue		120
Cyclo Therapeutics Inc
COSTS AND EXPENSES
Unrealized gain (loss) on investments	2,663
Hedge Funds
COSTS AND EXPENSES
Unrealized gain (loss) on investments	220	(504)
Day Three Labs Inc
COSTS AND EXPENSES
Equity in loss	(203)
RP Finance
COSTS AND EXPENSES
Equity in loss		$ (575)